Company: IMNN
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001493152-25-022120
Chunk: 6

Company: Imunon, Inc.
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 8
Chunk 6
---

  
    Manufacturing (CMC) 
     746  
     1,551  
     (805) 
     (51.9)%
  
    Subtotal 
     2,955  
     4,956  
     (2,001) 
     (40.4)%
  
    Research and development expenses 
     5,291  
     9,407  
     (4,116) 
     (43.8)%
  
    General and administrative expenses 
     5,098  
     5,580  
     (482) 
     (8.6)%
  
    Total operating expenses 
     10,389  
     14,987  
     (4,598) 
     (30.7)%
  
    Loss from operations 
    $(10,389) 
    $(14,987) 
    $(4,598) 
     (30.7)%

Note
6. Other Accrued Liabilities

Other
accrued liabilities at September 30, 2025 and December 31, 2024 include the following:

 Schedule of Other Accrued Liabilities

    September 30, 2025  
    December 31, 2024 
  
    Amounts due to contract research organizations and other contractual agreements 
    $910,501  
    $1,048,036 
  
    Accrued payroll and related benefits 
     1,687,690  
     1,945,111 
  
    Accrued professional fees and other 
     78,760  
     40,600 
  
    Total 
    $2,676,951  
    $3,033,747 

Note
7. Stockholders’ Equity

On
May 15, 2024, the Company filed with the U.S. Securities and Exchange Commission (“SEC”) a shelf registration statement on
Form S-3 (the “2024 Registration Statement”) for the offer and sale of up to $75 million of its securities. The 2024 Registration
Statement was declared effective on May 22, 2024. The 2024 Registration Statement is intended to provide the Company with flexibility
to raise capital in the future for general corporate purposes. As noted in the prospectus supplement that the Company filed on July 22,
2025, the